Form 4: Tharimmune Director Acquires 17,500 Stock Options

Tharimmune, Inc. Director Thomas Clay Kahler acquired 17,500 stock options with an exercise price of $3.075 per share.

Summary

• Thomas Clay Kahler, a Director of Tharimmune, Inc. (THAR), acquired 17,500 stock options.
• The options have an exercise price of $3.075 per share.
• The transaction date for the acquisition was November 3, 2025.
• These options become exercisable on November 3, 2025, and expire on November 3, 2035.
• Following this transaction, Mr. Kahler beneficially owns a total of 67,500 derivative securities.

Sentiment

Score: 6

Explanation: The filing reports a routine insider transaction (option grant) which is generally neutral but can be seen as slightly positive due to increased alignment of a director's interests with shareholders.

Positives

• The grant of stock options to Director Thomas Clay Kahler aligns his interests with those of shareholders, incentivizing long-term company performance.
• The options become exercisable immediately on the transaction date, indicating a current incentive.

Negatives

• No specific negative information is contained within this Form 4 filing.

Risks

• No specific risks are mentioned in this Form 4 filing, which is a routine disclosure of insider transactions.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction. It is a report of a past transaction.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a form of equity compensation to attract and retain talent and align management interests with shareholder value creation.

Comparison to Industry Standards

• The grant of stock options to directors is a standard compensation practice across various industries, including biotech, to incentivize long-term performance and align interests.
• The specific number of options and exercise price would typically be benchmarked against peer companies of similar market capitalization and stage of development, though this filing does not provide such comparative data.

Stakeholder Impact

• Shareholders: The grant of stock options to a director can align their interests with shareholders, potentially leading to decisions that enhance long-term shareholder value.
• Management/Directors: The options serve as a form of compensation and incentive for the director.

Key Dates

Recommendation

This Form 4 filing details a routine grant of stock options to a director, which is a standard compensation practice aimed at aligning management incentives with shareholder interests. It does not provide new material information that would fundamentally alter the investment thesis or warrant a change in a seasoned investor's recommendation.

Keywords

Tharimmune, THAR, Stock Options, Insider Transaction, Form 4, Director Compensation, Equity Grant, Beneficial Ownership